<SEC-DOCUMENT>0001193125-16-633203.txt : 20160627
<SEC-HEADER>0001193125-16-633203.hdr.sgml : 20160627
<ACCEPTANCE-DATETIME>20160627164802
ACCESSION NUMBER:		0001193125-16-633203
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160627
FILED AS OF DATE:		20160627
DATE AS OF CHANGE:		20160627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DBV Technologies S.A.
		CENTRAL INDEX KEY:			0001613780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36697
		FILM NUMBER:		161733819

	BUSINESS ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
		BUSINESS PHONE:		33(0)155427878

	MAIL ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d218004d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of June 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: 001-36697 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DBV
TECHNOLOGIES S.A. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>177-181 avenue Pierre Brossolette </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>92120 Montrouge France </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;Form 40-F </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated June 27, 2016.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><B>DBV TECHNOLOGIES S.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: June 27, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Schilansky</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Schilansky</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g218004g57y46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Press Release </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Montrouge, France, June 27, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">DBV Technologies
Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Expects to Report
Topline Results for PEPITES in 2H 2017 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies (Euronext: DBV &#150; ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty
biopharmaceutical company, today announced that it has reached its patient recruitment objective for PEPITES (<U>PE</U>anut <U>EPIT</U><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> <U>E</U>fficacy and <U>S</U>afety), the company&#146;s
pivotal Phase III trial of Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Peanut for the treatment of peanut allergic children. Recruitment in PEPITES exceeded initial expectations, with a total of 500 patients screened. As a
result, the company increased its initial randomization target of 330 patients to at least 350 patients. Viaskin Peanut is the company&#146;s lead product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology
platform that can deliver biologically active compounds to the immune system through the skin. Topline results from PEPITES are expected in the second half of 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;Today marks an important milestone for peanut allergic patients worldwide, as PEPITES is the first Phase III clinical trial in this disease to
successfully finalize recruitment,&#148; </I>said <B>Dr. David Fleischer</B>, Principal Investigator for the PEPITES trial and Associate Professor of Pediatrics, Children&#146;s Hospital Colorado. <I>&#147;We hope that the results in PEPITES will
reflect the positive data that we have observed in other Viaskin Peanut trials.&#148;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;We are extremely proud to see that due to the
enthusiasm from our trial&#146;s investigators and strong patient demand we were able to complete the recruitment milestone earlier than anticipated and well ahead of our expectations, taking us one step closer to the approval phase for Viaskin
Peanut,&#148; </I>said<I> </I><B>Dr. Pierre-Henri Benhamou</B><I>, </I>Chairman and Chief Executive Officer DBV Technologies.<I> &#147;This excitement for PEPITES captures the real need for a safe and effective treatment for peanut allergy, and we
are deeply thankful for our patients, caretakers and clinicians&#146; support during this short recruitment process.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About PEPITES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Peanut EPIT Efficacy and Safety Study (PEPITES) is a global, pivotal, double-blinded, placebo-controlled Phase III trial designed to evaluate the safety
and efficacy of Viaskin Peanut 250 &micro;g in children ages four to 11 years. During PEPITES, patients&#146; response will be assessed using a double-blind, and placebo controlled food challenge (DBPCFC). Patients will be randomized 2:1 to receive
either Viaskin Peanut 250 &micro;g or placebo for 12 months. The combined primary endpoint is based on a responder analysis after 12 months of treatment with Viaskin Peanut 250 &micro;g. For patients with a
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g218004g74o04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
baseline peanut protein eliciting dose (ED) equal to or less than 10 mg, a responder is defined as a patient with a peanut protein ED equal to or greater than 300 mg of peanut protein after 12
months of treatment. For subjects with a baseline ED greater than 10 mg, a responder is defined as a patient with a peanut protein ED equal to or greater than 1,000 mg of peanut protein after 12 months of treatment. As a secondary efficacy endpoint,
Cumulative Reactive Dose (CRD) will also be used in PEPITES to establish the total quantity of peanut protein that triggers patient reactions at month 12 versus placebo. Serological markers will also be measured at baseline, 3, 6, and 12 months in
order to characterize the immunological changes in patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About DBV Technologies</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies developed Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a proprietary technology platform with broad potential
applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, DBV&#146;s method of delivering biologically active compounds to the immune system through intact skin.
With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV&#146;s food allergies programs include
ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential
applications of its platform in vaccines and other immune diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one
ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: <U>www.dbv-technologies.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including statements reflecting management&#146;s expectations for clinical
development of our product candidates, future financial and operational performance and business outlook our research and development efforts and the commercial potential of our product candidates generally. These forward-looking statements are not
promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive
of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company&#146;s regulatory filings with the French Autorit&eacute; des March&eacute;s Financiers, the Company&#146;s Securities
and Exchange Commission filings and reports, including in the Company&#146;s Annual Report on Form 20-F for the year ended December 31, 2015 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future
events or circumstances or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Technologies Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Susanna Mesa</B><B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Senior Vice President,
Strategy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1&nbsp;212-271-0861 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">susanna.mesa@dbv-technologies.com </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g218004g74o04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contacts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Erinn White, Centron PR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 646-722-8822 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ewhite@centronpr.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contacts, Europe </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Caroline Carmagnol, Alize RP &#150; Relation Presse </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+33
(0)6 64 18 99 59 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">caroline@alizerp.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g218004g57y46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g218004g57y46.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M .U=I0Y;/YT &$VYW?-]>: % 5LESSG\J $7#']X>,<9- "#EMK'Y.WO0 O
M.T-\F: !L+G8>,=J  [5P8SS[4 'RA0RGY_K0 ?+M+,?G^M  -K9\P\]LT
MP<!SQCO0 #&=I;Y,T (?E.U3\G?VH &PA'EGZX- "D*N"A^;- !A-N=WS?6@
M  5MQ<X;/Y4 "X8_O#T'&30 BX8[6/R#I[T +QG:#\F: !L+D(>,=J  [5(\
ML\^U   H4,#\_P!:  ;2A9C\_P!: !=K9,AP??B@ 7#8WGC'&: #CA2?DS0
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MC&?2@!2=C;!C!H &_=$8[T &-@5AB@ QE-^1GZ4  'F98X&.* !3YIYXQ0
M[CLXP#0 ="4XQGTH &_= XQR*  CROF&*  C:GF#&>O2@ QN4OQF@!0/,)SC
MB@!!\Y"G& * #)SY?&,^E "$[#L&,&@!6_=$8[T !'EA6&* #;\N_(S]* %
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MJ7.!0 H_>'GL* $'SD(<8% "9(?RN,9ZXH "=C;!C!% #B/+(QB@ V[0&&*
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M<4 &-^   10 8XV;0&S0 'Y,H5!)H #^[/S '(H -IC(+ 8_E0 ;#C=@8]*
M#:7W%0,?SH ,>8?E &!0 @^;"!0"M "]/DVC.:  C9D$9)[T &WRR"P![4
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MSY*#MUH 5L. $&#_ "H 0\H$"_-0 N0JE2/F_G0 #"$AAUZ4 (OR$,PXQ^5
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M.T]N: %8 ;=AYH  =L6$8@GJ >M "878V3\WUH 50#G>3GZT (N"1N/&.*
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M #YCL)X!H /NDQ@_+G%  W[H$*>U "D>4,J>: $*[4\P'YJ %V[E+D_,/TH
M OF'YCTH 0?O"%8\8S]: #OY>?ESUH #F,[%/!_2@ 8>2?E/6@ *^7M93DG]
M: %V_+YF[YJ #:),LQP1^E "*/-.&.,4  RYV$_*/UH .A\L'Y<XH #^ZR%/
M:@!2/*P5/6@!-NU1(#\U !MW*9"?F% "@>;DL>E  !YF%8\4 )U_=Y^7.*
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M]^4_ZR7ZGL/\^U7&DV^:IJR)54ERPT1SY3?EQCV%=!@*5\WT&* $QOPF ,4
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M%  !Y@ P!B@!<9 CP!SUH 3_ %?R8!STH ,>2<<'(H -OE$,>: #81\_'TH
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M9+RX(QT,IQ_.JY(]A<\NY6)(;=+N/U.:HD3!"Y(.STS0 $$Y*@[?K0 N,GY
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5Z';:9H&FZ2H^S6X,@ZRO\SG\>WX8KAG5G/=G;"E&&R-.LC0* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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ME37F;4J3F_(]+L;"UTVV%O:0K%&.P')/J?4UYDIN;NST8Q459%FI*"@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % 'CNM?-KU^JC#"XDY_P"!&O8I_ O0\FI\
M;]2A_P!,\?/GK6A ?=RK#+'H: % *'YQNXXH %4KAF^[V'I0 FTD%@,)_=S0
M N"Y)3@?SH /OXV#:0.30 F,@(HPP[T +C *D9;/6@ QY>=_)(ZYH ,&,@OR
M/Y4 )M( 8C*>F: %*ELLOW?3/6@ *ES\GR\<T &-V%0;2._I0 F.-F/GSUH
M7[N5898]Z #!C/S_ #9'%  %*X9ON]AZ4 )M.-V/D_NYH 4J7)*<#N/6@ _U
MA^3Y2!R<T =SX;\'+LCO-5A^;[R0'^;?X?GZ5PUL1]F!VT:'69V]<)V!0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % 'CNM?)KU^RD9-Q)Q_P "->Q3^!>AY-3XWZE'_IIN&[-:$!]XEBP!'04
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M<I;LT48QV19J2@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
5@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g218004g74o04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g218004g74o04.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( '<#&@,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ -X:SJLAP-2NQC_IN_\ C7L>SAV1Y/M)]V(-:U5SL&I78(ZG
MSW_QH]G#L@]I/NP_MK5<F/\ M*[SZ^>_^-'LX=D'M)]V*=9U6/(_M*[/OY[?
MXT>SAV0>TGW8?VQJL?)U*[/_ &W?_&CV<.R#VD^[$_MC55 ?^T[LCT\]_P#&
MCV<.R#VD^[#^V=58;QJ=V!Z>>_\ C1[.'9![2?=BC6=5DR1J5V ./]>_^-'L
MX=D'M)]V(-:U63@:E=C'?SV_QH]G#L@]I/NQ?[9U4_)_:5V#GKY[_P"-'LX=
MD'M)]V']LZJGR?VE=D^OGO\ XT>SAV0>TGW8AUK58NNI79S_ --W_P :/9P[
M(/:3[L7^V-5CP3J5V?;SW_QH]G#L@]I/NP_MC5@-_P#:5W]//?\ QH]G#L@]
MI/NP_MC57RPU.[ [#SWY_6CV<.R#VD^[ :SJLAXU*[&/^F[_ .-'LX=D'M)]
MV(-:U5_D_M*[!'4^>_\ C1[.'9![2?=B_P!M:KGR_P"TKO/KY[?XT>SAV0>T
MGW8AUK58\K_:5V<]#Y[_ .-'LX=D'M)]V+_;.JQG)U*[.?\ IN_^-'LX=D'M
M)]V']L:JH#_VG=X]//?_ !H]G#L@]I/NP_MG52-XU*[ ]//?_&CV<.R#VD^[
M :SJLF2-2NP!Q_KW_P :/9P[(/:3[L!K.JR8 U*[&/\ INW^-'LX=D'M)]V
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M_C1[.'9![2?=@=:U6+@ZE=G(_P">[?XT>SAV0>TGW8?VSJL>"=2NR#_TW?\
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M//?_ !H]G#L@]I/NQ/[9U5E\P:G=@>GGO_C1[.'9![2?=B_VSJLG(U*[&/\
MIN_^-'LX=D'M)]V']LZJY"_VE=C'4^>_^-'LX=D'M)]V']M:KQ'_ &E=YSU\
M]_\ &CV<.R#VD^[$_MK54.S^TKLD]#Y[_P"-'LX=D'M)]V*=:U6(\ZE=G/\
MTW;_ !H]G#L@]I/NP_MC58\,=2NR/3SWX_6CV<.R#VD^[$_MC5L;_P"TKOZ>
M>_\ C1[.'9![2?=B_P!L:J^2-2NQCMY[_P"-'LX=D'M)]V UG59.FI78Q_TW
M?_&CV<.R#VD^[$&M:JYV?VE=@CJ?/;_&CV<.R#VD^[#^VM5R8_[2N\^OGO\
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ML>6",#F@ XX !#9]: #& 002V?6@ .%SO!/'K0 N-I!<$CW- "8P 2#M],T
M&,@E<[?KUH 7&3\@(X]: $&#M"@@B@ X^[@[\^M  < D,"6/3F@!<;6^<$\<
M<T  !7:6!V_7I0 F/ER =GIF@ QN+% <>QZT  PV/+!&!SS0 <'  (;/K0 $
M  @@[L^M !]TG>"3B@!<;2"X./<T (!@ D'9Z9H ,9!9<[?3- "XW'Y 0,>M
M !UVA00<>M "<<+@[\^M !P"0P);MS0 N-K?.">..: $ *E2P.WZ]* #'RYP
M=GIF@ QN+% <>QZT  ^;[@(XYYH !@X"@AAUYH ,  @@[L^M  ?ESO!)QZT
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M'I0 !B=JG.WUQUH 3<0"HSL]<4 +G82$R1]*  '9C82>.>*  ' # G=GIB@
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MD#Z8H ,G 4YV>N* #)4%5SL]<=* #.TX3)&/2@ SMVE22<>E !GHV3OSTQ0
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M 4C'K0 F=R! I!% "@[4*%3F@ 7]WD,I.?2@!%S&<LI.1V[4 *,J=^WC/2@
M.6^8+QZ>M  V9?N@C'K0 $^9A54C'Z4 &?EV;#F@ SL!4J23^M  N8R=P)R.
MU "*"AW%>#V]* #!W;]ORYZ4 # R$D+P/7O0 I/F$84C'K0 9W*J!2"._I0
M [4V%3F@ 7]WE64G/I0 +F/EE)SZ=J $ *_/MXSG% "D%OF"\ ]/6@ ;,GW0
M1B@ ;]X JJ1B@ SE0FPYH ,[ 4*DD]_6@ !,;'*DY]* %BCD:10D;.S<!5&3
M2;L%KFO:>%=9O'61;)HD)ZS$)C\#S^E92KTX]3:-&;Z&Q%\/KJ0[KB^BB]D0
MOG\\5B\7%;(U6%?5FC'X L<#SKN=F ZIM7^8-9O%RZ(T6%CU99C\#:0B;6\]
M\="SCC\@*AXJH4L-!$P\&:(J;?L[D?\ 71J7UFIW']7I]@'@S1%! MFY_P"F
MC?XT?6:G</J]/L"^#-$7I;/_ -_6_P :/K-3N'U>GV >#-#!R+9O^_C?XT?6
M:G</J]/L!\&:&3G[,W_?QO\ &CZS4[A]7I]@/@S1&ZVS_P#?UO\ &CZS4[A]
M7I]@/@S1" #;-Q_TT;_&CZS4[A]7I]@_X0S1-NW[,V/^NC?XT?6:G</J]/L
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MV?\ [^M_C1]9J=P^KT^P#P7H8.1;-G_KJW^-'UFIW#ZO3[!_PA>AYS]F;/\
MUT;_ !H^LU.X?5Z?8#X,T-NMLW_?UO\ &CZS4[A]7I]@/@S1",&V;_OXW^-'
MUFIW#ZO3[!_PAFB;<?9FQ_UT;_&CZS4[A]7I]@'@S1 NT6SX_P"NC?XT?6:G
M</J]/L \&:(O2V;_ +^-_C1]9J=P^KT^P#P9H:G(MF_[^-_C1]9J=P^KT^P?
M\(9H><_9FS_UT;_&CZS4[A]7I]@/@O0R<FV;/_75O\:/K-3N'U>GV ^#-$8Y
M-L__ '];_&CZS4[A]7I]@/@S1" /LS<=/WC?XT?6:G</J]/L'_"&:'MV_9FQ
M_P!=&_QH^LU.X?5Z?8!X,T0 C[,W/_31O\:/K-3N'U>GV >#-$4Y%L__ '];
M_&CZS4[A]7I]A!X+T-3D6SY_ZZM_C1]9J=P^KT^PO_"%Z'G/V9L_]=&_QH^L
MU.X?5Z?8#X,T0];9O^_C?XT?6:G</J]/L!\&:(>MLW_?QO\ &CZS4[A]7I]@
M/@S1"NW[,^/^NK?XT?6:G</J]/L \&:(%V_9GQ_UU;_&CZS4[A]7I]@'@S1%
MZ6S?]_&_QH^LU.X?5Z?8!X,T-3D6S_\ ?UO\:/K-3N'U>GV#_A#-#!R+9O\
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MSIC%1V18J2@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MAN,C\* !_P!WPI_"@!P1BZ+"&>1R % R6/T[T;!N=IHO@8_)<:JY'?R$//\
MP)A_(?G7#4Q72!V4\-UF=M##%;Q+%#&L<:C 51@"N)MMW9V))*R'TAA0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'AX!E..!@#M7N'C ,N?+X&WOB
M@ &03%QUZT !!C!7@Y% "[3$<Y!_"@! I51)D'VQ0!);N(Y1<-%'*!G]W(#M
M/UP12:NK#3LS1C_L_524\I=/N.B.K$QL?1@>1]<X]JS?/#7=&BY9:;%^Q,L4
M/V>>$B:QWI-#W>!QAL?3K^.:SE9NZZ_FBXW2L^GY&9<:-=J,VR&ZM2?DGA4L
M"/?'0^QK55([/1F;IM:K5%K3[&?2YX[FYB*S@C[- 5^>1_X3MZ@ \Y/I43DI
MKE6W4J,7%W?R'W-F9'CM3,B6UE&?M%PW*AR<MCU.> .^*%*VO5[(;C?3HBI+
M=Z?:C;:Z:D@Z>9<.Q8^^ 0!5*,GNR.:*T2,S80-^1],5J9BE"^6R![4 )@RG
ML, =J  9?Y.!CVH .03%QUZT !S'E>#D4 +M,1SD'/M0 @4H ^1],4 &TL/,
MR/IB@  ,N6R!CB@  ,H X&!0 #+#9QP>M  <H-G')'.* +FG:7=ZA=+;6D7F
M,W5B/E0>I/85$YQ@KLJ$'-V1Z5H7AJST-"Z?O;EA\TK#GZ =A7F5:TJGH>C3
MI1I^IM5B;!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >'XWG
MY.,#DYKW#Q@X;"J,,.] !@<ICYL]: #&P$.,D]\T *%*'+_-Z4 (%*@,?N^F
M>E !M)!8<+Z9H ,;R2G Z&@#7L=3600Q7,DD4D _<W2<O%_LD?Q+[?\ ZJQE
M#K'[C6,^C^\TTC+L7B@@ED/)EL;X0;O<H>A_ 5EMHW]ZN:+NOP=AK/#9!S(\
M-DSC#,D_VBY?V##A<^O%.SEY_@@TCY?BS$OK\S*D"Q^5:1_ZN(-GGU)[GW_*
MMXPY=7N8RE?1;%(*8R"W([#TJR V'&['R_W<T !4L25X7T]: #&\_)\N!SS0
M 8W *HPP[T &.-F/FSUH ,;,AQDF@ V[#E^?3GI0 !2N&/W?3/2@ VDC<.%]
M,T &-Y)3@=/K0 8WXV#:1WS0 8R H&&!ZT :NBZ!=:S,T<2A(U(WS-T7_$^U
M95*L::U-*=-S>AZ?INF6VDV:VUJF%'5CRS'U)KRYS<W=GI0@H*R+E06% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MWMHQ'$@X KRY2<G=GHQBHJR)JDH* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M3T6B.^G0C#5[G05SFX4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MK*)2IR&(W,/Q.36,JLY;LUC3A'9&A69H% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
A !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
